Top

Published in:

01-08-2020 | SCLC | Letter to the Editor

A rare case of Opsoclonus-Myoclonus associated with SCLC

Authors: M. Lebeer, M. Montagna, S. Coito, T. Reynders, J. Raskin

Published in: Acta Neurologica Belgica | Issue 4/2020

Excerpt

We report a case of a patient with a newly diagnosed small-cell lung cancer (SCLC), with paraneoplastic Opsoclonus-Myoclonus Syndrome (p-OMS) as the presenting symptom. Patients with OMS may have very debilitating symptoms, despite an albeit limited tumor load. Furthermore, OMS may be refractory to treatment, even in case of primary tumor response. Hence it represents a real challenge for the clinician, and a multidisciplinary approach (neurologist–oncologist) is recommended. …

Available only for authorised users

Oh S-SY, Kim J-S, Dieterich M et al (2019) Update on opsoclonus-myoclonus syndrome in adults. J Neurol 266:1541–1548CrossRef

Wong AM, Mussalam S, Tomlinson RD et al (2001) Opsoclonus in three dimensions: oculographic, neuropathologic and modelling correlates. J Neurol Sci 189:71–81CrossRef

Armangué T, Sabater L, Torres-Vega E et al (2016) Clinical and immunological features of opsoclonus-myoclonus syndrome in the era of neuronal cell surface antibodies. JAMA Neurol 73(4):417–424CrossRef

Bataller L, GrausF SA et al (2001) Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus–myoclonus. Brain 124(2):437–443CrossRef

Horn L, Mansfield A, Mok T et al (2018) First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer (IMPOWER 133). N Engl J Med 379:2220–2229CrossRef

Paz-Ares L, Dvorkin M, Chen Y et al (2019) Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small–cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase 3 trial. Lancet 394(10212):1929–1939CrossRef

Graus F, Dalmau J (2019) Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Rev Clin Oncol 16(9):535–548CrossRef

de Alarcon PA, Matthay KK, London WB et al (2018) Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. Lancet Child Adolesc 2:25–34CrossRef

Rosenfeld M, Dalmau J (2013) Diagnosis and management of paraneoplastic neurologic disorders. Curr Treat Options Oncol 14:4CrossRef

10.

Shams’ili S, de Beukelaar J, Gratama JW et al (2006) An uncontrolled trial of Rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol 253:16CrossRef

11.

Pranzatelli MR, Tate ED, Travelstead AL et al (2006) Rituximab (anti-CD20) adjunctive therapy for opsoclonus–myoclonus syndrome. J Pediatr Hematol Oncol 28:585–593CrossRef

Title: A rare case of Opsoclonus-Myoclonus associated with SCLC
Authors: M. Lebeer
M. Montagna
S. Coito
T. Reynders
J. Raskin
Publication date: 01-08-2020
Publisher: Springer International Publishing
Keywords: SCLC
Paraneoplastic Syndromes
SCLC
Cytostatic Therapy
Published in: Acta Neurologica Belgica / Issue 4/2020
Print ISSN: 0300-9009
Electronic ISSN: 2240-2993
DOI: https://doi.org/10.1007/s13760-020-01402-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A rare case of Opsoclonus-Myoclonus associated with SCLC

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2020

Altered plasma visfatin levels and insulin resistance in patients with Alzheimer’s disease

Spinal cord infarction due to fibrocartilaginous embolism

Erythropoietin-induced cluster of seizures in two children with cerebral palsy

The sensitivity of event-related potentials/fields to logopedic interventions in patients with stroke-related aphasia

Nocturnal blood pressure changes in Parkinson’s disease: correlation with autonomic dysfunction and vitamin D levels

Attention-deficit hyperactivity disorder in Brazilian patients with phenylketonuria